A therapeutic Her2/neu vaccine targeting dendritic cells preferentially inhibits the growth of low Her2/neu–expressing tumor in HLA-A2 transgenic mice (2016)
- Authors:
- Autor USP: FERREIRA, LUIS CARLOS DE SOUZA - ICB
- Unidade: ICB
- DOI: 10.1158/1078-0432.CCR-16-0044
- Subjects: MICROBIOLOGIA; CÉLULAS DENDRÍTICAS; ORGANISMOS GENETICAMENTE MODIFICADOS; CAMUNDONGOS; VACINAS; NEOPLASIAS MAMÁRIAS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher place: Philadelphia
- Date published: 2016
- Source:
- Título: Clinical Cancer Research
- ISSN: 1557-3265
- Volume/Número/Paginação/Ano: v. 16, n. 22, p. 4133-4144, 2016
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: bronze
-
ABNT
TRAN, Thi et al. A therapeutic Her2/neu vaccine targeting dendritic cells preferentially inhibits the growth of low Her2/neu–expressing tumor in HLA-A2 transgenic mice. Clinical Cancer Research, v. 16, n. 22, p. 4133-4144, 2016Tradução . . Disponível em: https://doi.org/10.1158/1078-0432.CCR-16-0044. Acesso em: 08 out. 2024. -
APA
Tran, T., Dransart, E., Gey, A., Merillon, N., Lone, Y. C., Godefroy, S., et al. (2016). A therapeutic Her2/neu vaccine targeting dendritic cells preferentially inhibits the growth of low Her2/neu–expressing tumor in HLA-A2 transgenic mice. Clinical Cancer Research, 16( 22), 4133-4144. doi:10.1158/1078-0432.CCR-16-0044 -
NLM
Tran T, Dransart E, Gey A, Merillon N, Lone YC, Godefroy S, Sibley C, Ferreira LC de S, Medioni J, Oudard S, Johannes L, Tartour E. A therapeutic Her2/neu vaccine targeting dendritic cells preferentially inhibits the growth of low Her2/neu–expressing tumor in HLA-A2 transgenic mice [Internet]. Clinical Cancer Research. 2016 ; 16( 22): 4133-4144.[citado 2024 out. 08 ] Available from: https://doi.org/10.1158/1078-0432.CCR-16-0044 -
Vancouver
Tran T, Dransart E, Gey A, Merillon N, Lone YC, Godefroy S, Sibley C, Ferreira LC de S, Medioni J, Oudard S, Johannes L, Tartour E. A therapeutic Her2/neu vaccine targeting dendritic cells preferentially inhibits the growth of low Her2/neu–expressing tumor in HLA-A2 transgenic mice [Internet]. Clinical Cancer Research. 2016 ; 16( 22): 4133-4144.[citado 2024 out. 08 ] Available from: https://doi.org/10.1158/1078-0432.CCR-16-0044 - Avaliação das propriedades imunológicas e papel vacinal da flagelina fliCi de Salmonella enterica pv Typhimurium
- Expression of enterotoxigenic Escherichia coli proteins by genetically modified Bacillus subtilis strains as a new approach to develop mucosal vaccines
- Immunogenicity of flagelins FliCi e FliCd following oral immunization of mice with attenuated salmonella strains
- Evaluation of the genetic diversity among enterotoxigenic Escherichia coli (ETEC) strains isolated from humans in Brazil and Argentina
- Construção de uma vacina de DNA bivalente contra os vírus do papiloma e herpes simplex humano
- A DNA vaccine encoding the enterohemorragic Escherichia coli shiga-like toxin 2 'A ind.2' and B subunits confers protective immunity to shiga toxin challenge in the murine model
- Produção e purificação da flagelina FliCi de S. Typhimurium
- Surface expression of adhesins enhances the vaccine potential of orally delivered Bacillus subtilis strains
- Immune responses and therapeutic antitumor effects of an experimental DNA vaccine encoding human Papillomavirus type 16 oncoproteins genetically fused to Herpesvirus glycoprotein D
- Characterization of a DNA vaccine encoding the HPV-16 E7 oncoprotein genetically fused to the N-terminal domain of Salmonella enterica SV Müenchen FLICd flagellin
Informações sobre o DOI: 10.1158/1078-0432.CCR-16-0044 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas